<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Digoxin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int480-digoxin.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int480-digoxin.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int480-digoxin.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int478-cardiac-glycosides.htm">Cardiac Glycosides</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int478-cardiac-glycosides.htm" title="Previous: Cardiac Glycosides">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1160-certolizumab-pegol.htm" title="Next: Certolizumab pegol">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Digoxin</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Digoxin</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1-acarbose.htm">Acarbose</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly reduced by</span> <span>acarbose</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>alprazolam</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>amiodarone</span> <span>(halve dose of <span>digoxin</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>possibly reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1008-bleomycin.htm">Bleomycin</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>bleomycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int3-captopril.htm">Captopril</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>captopril</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1123-carmustine.htm">Carmustine</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>carmustine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int335-chloroquine-and-hydroxychloroquine.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>chloroquine and hydroxychloroquine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>ciclosporin</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span> <span>digoxin</span> <span>given with</span> <span>colchicine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int502-cyclophosphamide.htm">Cyclophosphamide</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>cyclophosphamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int821-cytarabine.htm">Cytarabine</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>cytarabine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int506-doxorubicin.htm">Doxorubicin</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>doxorubicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>dronedarone</span> <span>(halve dose of <span>digoxin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>etravirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int131-gentamicin.htm">Gentamicin</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>gentamicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1106-lenalidomide.htm">Lenalidomide</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>lenalidomide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>lercanidipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int166-macrolides.htm">Macrolides</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>macrolides</span> <span>(increased risk of toxicity)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Telithromycin</p></div></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td><p><span>possible increased risk of bradycardia when </span> <span>digoxin</span> <span>given with</span> <span>mefloquine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int503-melphalan.htm">Melphalan</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>melphalan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>methotrexate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int133-neomycin.htm">Neomycin</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>reduced by</span> <span>neomycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int474-nicardipine.htm">Nicardipine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>nicardipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>nifedipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int658-penicillamine.htm">Penicillamine</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly reduced by</span> <span>penicillamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1110-potassium-canrenoate.htm">Potassium Canrenoate</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>potassium canrenoate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int32-prazosin.htm">Prazosin</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>prazosin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int514-procarbazine.htm">Procarbazine</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>procarbazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>propafenone</span> <span>(halve dose of <span>digoxin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly slightly increased by</span> <span>proton pump inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>quinine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>ranolazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>rilpivirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int726-salbutamol.htm">Salbutamol</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly reduced by</span> <span>salbutamol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1089-sitagliptin.htm">Sitagliptin</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>sitagliptin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int549-spironolactone.htm">Spironolactone</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>spironolactone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>reduced by</span> <span>St John's wort</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int818-sulfasalazine.htm">Sulfasalazine</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>possibly reduced by</span> <span>sulfasalazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1158-tolvaptan.htm">Tolvaptan</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>tolvaptan</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td><p><span>plasma concentration of </span> <span>digoxin</span> <span>possibly increased by</span> <span>trimethoprim</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>digoxin</span> <span>increased by</span> <span>verapamil</span> <span>, also increased risk of AV block and bradycardia</span>  </p></td><td></td></tr><tr><td><a href="bnf_int815-vincristine.htm">Vincristine</a></td><td><p><span>absorption of </span> <span>digoxin</span> <span>tablets possibly reduced by</span> <span>vincristine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Digoxin</strong> belongs to <strong>Cardiac Glycosides</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>cardiac glycosides</span> <span>if hypokalaemia occurs with</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>cardiac glycosides</span> <span>if hypokalaemia occurs with</span> <span>amphotericin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>increased risk of AV block and bradycardia when </span> <span>cardiac glycosides</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int465-calcium-salts.htm">Calcium Salts</a></td><td><p><span>arrhythmias can be precipitated when </span> <span>cardiac glycosides</span> <span>given with large intravenous doses of</span> <span>calcium salts</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> see also Antacids</p></div></td></tr><tr><td><a href="bnf_int593-colestipol.htm">Colestipol</a></td><td><p><span>absorption of </span> <span>cardiac glycosides</span> <span>possibly reduced by</span> <span>colestipol</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption </p></div></td></tr><tr><td><a href="bnf_int592-colestyramine.htm">Colestyramine</a></td><td><p><span>absorption of </span> <span>cardiac glycosides</span> <span>possibly reduced by</span> <span>colestyramine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</p></div></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span>increased risk of hypokalaemia when </span> <span>cardiac glycosides</span> <span>given with</span> <span>corticosteroids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>cardiac glycosides</span> <span>if hypokalaemia occurs with</span> <span>loop diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td class="cAI"><p><span>increased cardiac toxicity with </span> <span>cardiac glycosides</span> <span>if hypokalaemia occurs with</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td><p><span>plasma concentration of </span> <span>cardiac glycosides</span> <span>possibly increased by</span> <span>NSAIDs</span> <span>, also possible exacerbation of heart failure and reduction of renal function</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span> <span>cardiac glycosides</span> <span>possibly reduced by</span> <span>sucralfate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span>risk of ventricular arrhythmias when </span> <span>cardiac glycosides</span> <span>given with</span> <span>suxamethonium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td><p><span>possible increased risk of bradycardia when </span> <span>cardiac glycosides</span> <span>given with</span> <span>tizanidine</span> <span></span>  </p></td><td></td></tr></tbody></table></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int478-cardiac-glycosides.htm">Previous: Cardiac Glycosides</a> | <a class="top" href="bnf_int480-digoxin.htm#">Top</a> | <a accesskey="]" href="bnf_int1160-certolizumab-pegol.htm">Next: Certolizumab pegol</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>